Market Overview:
The global sickle-cell anemia therapeutics market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of sickle-cell anemia, rising awareness about available treatments, and technological advancements in the field of sickle-cell anemia therapeutics. The global sickle-cell anemia therapeutics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into blood transfusion therapy, pharmacotherapy, and bone marrow transplant. The blood transfusion therapy segment dominates the global sickle-cell anemia therapeutics market owing to its high adoption rate across all regions. On the basis of application,the global sickle cell anemia therapeuticsmarket is divided into child patients and adult patients segments.
Product Definition:
Sickle-cell anemia is a genetic disorder characterized by red blood cells that are shaped like sickles. These abnormal cells can block blood flow and cause pain, organ damage, and other serious problems. Sickle-cell anemia therapies are used to help prevent or treat the complications of this disorder.
Blood Transfusion:
Blood transfusion is the process of replacing blood lost from a patient's body. It is mainly done to replace blood volume that has been destroyed or removed from the body through diarrhea, major surgery, etc. The global Blood Transfusion market size spans product types and applications across Sickle-cell anemia therapeutics market.
Pharmacotherapy:
Pharmacotherapy is the use of drugs to treat a disease. In sickle-cell anemia therapeutics, drugs are used to reduce pain and prevent complications from occurring in people with sickle cell disease. The global pharmacotherapy market is expected to grow at a lucrative rate during the forecast period due to factors such as increasing prevalence of diseases, rising awareness about available treatments among patients & healthcare professionals and technological advancements in drug discovery & development processes.
Application Insights:
Based on the application, the global market is segmented into child, adult and other. The other segment includes patients who have undergone splenectomy or haven¢â‚¬â„¢t undergone any treatment yet. In 2016, the child segment dominated with a share of over 80% in terms of revenue generation. This trend is expected to continue over the forecast period due to rising incidences of SCA among children below 5 years old globally and increasing awareness about available treatments for this disease among parents globally. As per estimates from WHO in 2017, around 10 million people are living with sickle cell disease worldwide while another 50-150 thousand new cases are reported every year; however exact numbers are not known as data regarding this condition is unavailable in many countries due to lack of awareness and reporting guidelines amongst healthcare professionals as well as patients themselves.
Regional Analysis:
North America dominated the market in terms of revenue share in 2016. The high prevalence of sickle cell disease coupled with a rise in healthcare expenditure and favorable government initiatives is anticipated to drive the market growth over the forecast period. For instance, according to data published by National Institute of Health (NIH), around 60,000 babies are born annually with SCA worldwide. In addition, an estimated 1 million people suffer from SCA annually and only 10% die during infancy owing to transfusion; however 50% do not survive without treatment [1]. Thus these factors are expected to boost demand for therapeutics for treatment & prevention purposes over the forecast period.
Asia Pacific is expected witness lucrative CAGR due its low penetration rate coupled with increasing awareness about available treatments & preventive measures taken by patients & their families against this condition along with rising healthcare expenditure levels within this region which has led it being named as one of the fastest growing regions within this industry [2].
Growth Factors:
- Increasing incidence of sickle-cell anemia
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective therapies for sickle-cell anemia
- Technological advancements in the field of sickle-cell anemia therapeutics
- Growing number of clinical trials being conducted on new drugs and therapies for treating sickle-cell anemia
Scope Of The Report
Report Attributes
Report Details
Report Title
Sickle-cell Anemia Therapeutics Market Research Report
By Type
Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant
By Application
Global Sickle-cell Anemia Therapeutics Market Share by User: 2016 VS 2021 VS 2027, Child, Adult
By Companies
Addmedica, Gamida Cell, GlycoMimetics, Pfizer, Novartis, Global Blood Therapeutics, Micelle BioPharma, Bluebird Bio, Prolong Pharmaceuticals, Modus Therapeutics, Sangamo Biosciences, Bioverativ, Imara, Ironwood Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
175
Number of Tables & Figures
123
Customization Available
Yes, the report can be customized as per your need.
Global Sickle-cell Anemia Therapeutics Market Report Segments:
The global Sickle-cell Anemia Therapeutics market is segmented on the basis of:
Types
Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Global Sickle-cell Anemia Therapeutics Market Share by User: 2016 VS 2021 VS 2027, Child, Adult
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Addmedica
- Gamida Cell
- GlycoMimetics
- Pfizer
- Novartis
- Global Blood Therapeutics
- Micelle BioPharma
- Bluebird Bio
- Prolong Pharmaceuticals
- Modus Therapeutics
- Sangamo Biosciences
- Bioverativ
- Imara
- Ironwood Pharmaceuticals
Highlights of The Sickle-cell Anemia Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
- By Application:
- Global Sickle-cell Anemia Therapeutics Market Share by User: 2016 VS 2021 VS 2027
- Child
- Adult
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sickle-cell Anemia Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sickle-cell anemia therapeutics is a term used to describe treatments for sickle-cell disease. These treatments can include medications, surgery, and other therapies.
Some of the key players operating in the sickle-cell anemia therapeutics market are Addmedica, Gamida Cell, GlycoMimetics, Pfizer, Novartis, Global Blood Therapeutics, Micelle BioPharma, Bluebird Bio, Prolong Pharmaceuticals, Modus Therapeutics, Sangamo Biosciences, Bioverativ, Imara, Ironwood Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Sickle-cell Anemia Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Sickle-cell Anemia Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Sickle-cell Anemia Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Sickle-cell Anemia Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Sickle-cell Anemia Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Sickle-cell Anemia Therapeutics Market Size and Y-o-Y Growth
4.5.2 Sickle-cell Anemia Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Blood Transfusion
5.2.2 Pharmacotherapy
5.2.3 Bone Marrow Transplant
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Global Sickle-cell Anemia Therapeutics Market Share by User: 2016 VS 2021 VS 2027
6.2.2 Child
6.2.3 Adult
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Sickle-cell Anemia Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Sickle-cell Anemia Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Blood Transfusion
9.6.2 Pharmacotherapy
9.6.3 Bone Marrow Transplant
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Global Sickle-cell Anemia Therapeutics Market Share by User: 2016 VS 2021 VS 2027
9.10.2 Child
9.10.3 Adult
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Blood Transfusion
10.6.2 Pharmacotherapy
10.6.3 Bone Marrow Transplant
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Global Sickle-cell Anemia Therapeutics Market Share by User: 2016 VS 2021 VS 2027
10.10.2 Child
10.10.3 Adult
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Blood Transfusion
11.6.2 Pharmacotherapy
11.6.3 Bone Marrow Transplant
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Global Sickle-cell Anemia Therapeutics Market Share by User: 2016 VS 2021 VS 2027
11.10.2 Child
11.10.3 Adult
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Blood Transfusion
12.6.2 Pharmacotherapy
12.6.3 Bone Marrow Transplant
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Global Sickle-cell Anemia Therapeutics Market Share by User: 2016 VS 2021 VS 2027
12.10.2 Child
12.10.3 Adult
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Blood Transfusion
13.6.2 Pharmacotherapy
13.6.3 Bone Marrow Transplant
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Global Sickle-cell Anemia Therapeutics Market Share by User: 2016 VS 2021 VS 2027
13.10.2 Child
13.10.3 Adult
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Sickle-cell Anemia Therapeutics Market: Competitive Dashboard
14.2 Global Sickle-cell Anemia Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Addmedica
14.3.2 Gamida Cell
14.3.3 GlycoMimetics
14.3.4 Pfizer
14.3.5 Novartis
14.3.6 Global Blood Therapeutics
14.3.7 Micelle BioPharma
14.3.8 Bluebird Bio
14.3.9 Prolong Pharmaceuticals
14.3.10 Modus Therapeutics
14.3.11 Sangamo Biosciences
14.3.12 Bioverativ
14.3.13 Imara
14.3.14 Ironwood Pharmaceuticals
